Skip to content

Freedom SOLO Stentless Heart Valve Study

Clinical Investigation of the Freedom SOLO Stentless Heart Valve in North America

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01115907
Acronym
SOLO
Enrollment
251
Registered
2010-05-04
Start date
2010-12-31
Completion date
2014-10-31
Last updated
2015-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Insufficiency, Aortic Stenosis

Keywords

Aortic, Valve replacement

Brief summary

The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the Freedom SOLO heart valve.

Detailed description

The SOLO clinical investigation is a prospective, non-randomized, multicenter trial of the SOLO Freedom heart valve implanted in patients requiring aortic valve replacement.

Interventions

DEVICEFreedom SOLO Stentless Heart Valve

Freedom SOLO Stentless Heart Valve

Sponsors

Sorin Group USA, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subject is male or female 18 years old or older. * The subject or subject's legal representative is willing to sign the informed consent. * The subject which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement. * Any subject amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures. * The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable). * Subject will be available to the investigator(s) for postoperative follow-up beyond one year.

Exclusion criteria

* The subject has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position. * The subject requires a double or multiple valve replacement (a valve repair is not considered an exclusion criterion). * The subject has a previously implanted SOLO valve, within the clinical study, that requires replacement. * The subject has active endocarditis or myocarditis. * The subject is or will be participating in a concomitant research study of an investigational product. * The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent. * The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject. * The subject is pregnant, planning to become pregnant or lactating. * The subject has a congenital bicuspid aortic valve. * The subject is known to be noncompliant or is unlikely to complete the study. * The subject is undergoing renal dialysis for chronic renal failure or has been diagnosed with hyperparathyroidism. * The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery. * The subject has extensive calcification of the aortic root where removal of the calcified tissue cannot be achieved. * The subject has a significantly dilated aortic root that is not surgically corrected. * The subject requires replacement of the aortic root / full root procedure.

Design outcomes

Primary

MeasureTime frameDescription
Safety will be determined by incidence rate of adverse events1 yearThe complication and survival rates for the SOLO valve are comparable to appropriate historical controls manifested as objective performance criteria (OPCs) and to that reported in the literature for other stentless bioprostheses and stented pericardial valves.

Secondary

MeasureTime frameDescription
Efficacy will be determined by hemodynamics1 yearThe hemodynamic performance of the SOLO valve will be compared to that reported in the literature for other stentless bioprostheses and stented pericardial valves.
Effectiveness will be determined by NYHA Classification comparisons1 yearClinically significant improvement in overall patient condition by comparison of preoperative and postoperative NYHA functional classifications.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026